An interventional study of DC-Stimulator MC and DC-Stimulator MC in Glaucoma, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Glaucoma with a site in Taiwan — 3 open to participants now, 3 under way, none of them phase 3. Glaucoma · Taiwan.
Among the 14 studies in Glaucoma with a site in Taiwan, this one is the only one that started in 2026, is one of 3 with no phase, and was the 13th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →3 of the 14 studies in Glaucoma with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
China Medical University Hospital · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 188 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 47 across the 8 interventional studies, 230 across the 6 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 9 most frequent:
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
National Taiwan University Hospital has 4 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Glaucoma with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 10 days of repeated transcranial alternating current stimulation in hospital.
Device: DC-Stimulator MC
Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
Device: DC-Stimulator MC
Experimental:Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
Sham Comparator:Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Time frame: From treatment initiation to 26 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Time frame: From treatment initiation to 12 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Time frame: From treatment initiation to 19 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Time frame: From treatment initiation to 166 days after treatment initiation
Change in sensitivity at each of the 52 test points in the 24-2 visual field from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 19 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart.
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Time frame: From treatment initiation to 12 days after treatment initiation]
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Time frame: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Time frame: From treatment initiation to 166 days after treatment initiation
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 23 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →